• In July 2026, Pulse Biosciences, Inc. reported that its pivotal NANOPULSE-AF Study of the nPulse System for atrial fibrillation had passed the enrollment midpoint, highlighting rapid recruitment since the study’s April 2026 start and real-world alignment with first-line ablation practice.
• This pace of enrollment, supported by early safety and efficacy signals and an intuitive nano-PFA catheter, underscores growing clinician enthusiasm for the nPulse platform in a competitive cardiac ablation landscape.
• With enrollment crossing its midpoint on the back of strong investigator enthusiasm, we’ll explore how this shapes Pulse Biosciences’ investment narrative.

We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Pulse Biosciences Investment Narrative Recap

To own Pulse Biosciences, you need to believe nanosecond PFA can win meaningful share in thyroid and atrial fibrillation procedures despite early stage revenue and ongoing losses. The rapid enrollment midpoint in the NANOPULSE-AF pivotal trial looks supportive for the near term cardiac data catalyst, but it does not yet reduce the key risks around clinical outcomes, regulatory review and eventual commercial adoption.

Among recent developments, the April 2026 Heart Rhythm data on the nPulse Cardiac Catheter system is most relevant here, with European feasibility results showing strong pulmonary vein isolation durability and efficient procedure metrics. Together with the fast NANOPULSE-AF enrollment, this creates a clearer line of sight to pivotal data that could influence reimbursement decisions, guideline inclusion and how investors weigh the company’s cash burn against future revenue potential.

Yet alongside the excitement around rapid AF trial enrollment, investors should also be aware of the risk that...

Pulse Biosciences' narrative projects $39.2 million revenue and $4.6 million earnings by 2029. This requires 273.6% yearly revenue growth and an $79.2 million earnings increase from -$74.6 million today.

Uncover how Pulse Biosciences' forecasts yield a $30.67 fair value, a 19% downside to its current price.

Exploring Other Perspectives

Before this midpoint news, the most optimistic analysts were already assuming revenue could rise about 311% annually to roughly US$52.3 million by 2029, which is far more aggressive than the baseline view and shows how differently you and other investors might interpret fast AF enrollment and data quality.

Explore another fair value estimate on Pulse Biosciences - why the stock might be worth 19% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Pulse Biosciences research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Pulse Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pulse Biosciences' overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.